Repare Therapeutics (Repare Therapeutics) FCF Margin % : -218.85% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Repare Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Repare Therapeutics's Free Cash Flow for the three months ended in Dec. 2023 was $-28.55 Mil. Repare Therapeutics's Revenue for the three months ended in Dec. 2023 was $13.05 Mil. Therefore, Repare Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was -218.85%.

As of today, Repare Therapeutics's current FCF Yield % is -95.64%.

The historical rank and industry rank for Repare Therapeutics's FCF Margin % or its related term are showing as below:

RPTX' s FCF Margin % Range Over the Past 10 Years
Min: -6163.7 Med: -701.8 Max: -0.21
Current: -252.47

During the past 7 years, the highest FCF Margin % of Repare Therapeutics was -0.21%. The lowest was -6163.70%. And the median was -701.80%.

RPTX's FCF Margin % is ranked worse than
57.06% of 1034 companies
in the Biotechnology industry
Industry Median: -148.935 vs RPTX: -252.47

Repare Therapeutics FCF Margin % Historical Data

The historical data trend for Repare Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repare Therapeutics FCF Margin % Chart

Repare Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-6,163.70

-1,151.13

-0.21

-252.47

Repare Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-153.41	-568.18	-117.07	-1,522.46	-218.85

Competitive Comparison of Repare Therapeutics's FCF Margin %

For the Biotechnology subindustry, Repare Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Repare Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Repare Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Repare Therapeutics's FCF Margin % falls into.

Repare Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Repare Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-129.096	/	51.133
	=	-252.47 %

Repare Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-28.554	/	13.047
	=	-218.85 %

Repare Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Repare Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Repare Therapeutics (Repare Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Repare Therapeutics Inc (NAS:RPTX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

7210 Frederick-Banting Street, Suite 100, Saint-Laurent, QC, CAN, H4S 2A1

Website

https://www.reparerx.com

Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.

Executives

Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Michael Zinda	officer: EVP, Chief Science Officer	C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1
Susan Molineaux	director	C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
Davis Jerel	director, 10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures V, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage I, L.p.	10 percent owner	ONE SANSOME, SUITE 1650, SAN FRANCISCO CA 94104
Thomas Civik	director	C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Trading Fund Os Lp	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104